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Background
Allergen microarray testing is increasingly used as a
diagnostic tool for complex allergies, but its potential as
a follow-up means has not been established yet.
Objective
To report on the specific insights brought by allergen
microarray follow-up in 38 patients from Marseille
(Southern France).
Methods
From 2010 through 2013, allergen microarray testing
(ISAC®, ThermoFisher Phadia) was performed more
than once in 38 pediatric patients according to their
clinical status, skin prick testing and previous laboratory
results. A retrospective analysis of allergen microarray
results is presented here.
Results
Median age was 6 years (10 months to 17 years) when
ISAC® was first performed, and 8 years (22 months to
18 years) when the latest ISAC® was performed. With
respect to the number and intensity of IgE reactivities,
ISAC® follow-up results entered one of the following
categories: progression (16), stability (12), attenuation (8).
Two patients displayed complex alterations of their
molecular profile over time. In most cases, ISAC follow-
up provided aid for the management of food exclusion or
reintroduction regimens. Storage protein reactivity was the
most frequent setting, but transition from one molecular
profile to another, which were not clinically distinguish-
able, such as lipid tranfer proteins versus thaumatin-like
proteins, was als noted. Complex cross-reactivity patterns
or allergy to components which are unavailable for indivi-
dual testing (sesame Ses i 1, thaumatin-like Act d 2, 7S
vicillins other than those from Fabaceae, wheat Tri a 14)
gained better insight from repeated ISAC assays. Finally,
sequential “allergen landscape views” improved the under-
standing of the patient’s biological and clinical evolution.
Conclusion and clinical relevance
Sequential allergen microarray testing during the follow-
up proved useful for the management and prognostic
evaluation of complex polyallergic patients. Despite
yielding semi-quantitative results, allergen microarray
testing also helped monitoring reactivity to selected
allergens such as thaumatin-like protein Act d 2. Finally,
sequential allergen microarray testing provided a follow-
up of each patient’s progression during the atopic
march, thus contributing to prognostic evaluation.
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